Aromatase

Breast cancer prevention drug approved for post-menopausal women in the UK – here's how it works

Retrieved on: 
Wednesday, November 8, 2023
Woman, Breast, Menopause, Testosterone, Obesity, Androstenedione, Anastrozole, Cell, Breast cancer, NHS, Disease, Risk, Cancer, Neoplasm, Hormone, Letrozole, Osteoporosis, Fracture, Patient, Bone density, Aromatase, Enzyme inhibitor, Birth control, Dietary supplement, Medical imaging

A drug that can halve the risk of developing breast cancer in post-menopausal women has been approved for use in the UK.

Key Points: 
  • A drug that can halve the risk of developing breast cancer in post-menopausal women has been approved for use in the UK.
  • This drug, called anastrozole, could benefit an estimated 289,000 women in the UK who are at increased risk of breast cancer.
  • Anastrozole was already approved for use in the UK as a breast cancer treatment.
  • The key to anaztrozole’s success both in treating and preventing breast cancer, is due to its effects on the body’s oestrogen levels.

ORSERDU™ Now Available from Onco360 for the Treatment of Postmenopausal Women or Adult Men, with ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer with Disease Progression Following at Least One Line of Endocrine Therapy

Retrieved on: 
Thursday, February 2, 2023
Biotechnology, FDA, Health, Pharmaceutical, Oncology, Woman, Hope, National Cancer Institute (Egypt), HER2, Breast cancer, Specialty pharmacy, Patient, HIV disease progression rates, Death, Therapy, SEER, United, Aromatase, Phase, Progression-free survival, ESR1, Fulvestrant, PFS, Birth control, Medical imaging, Epidemiology

“Onco360 is honored to partner with Stemline Therapeutics and become a specialty pharmacy provider for ORSERDU patients,” said Benito Fernandez, Chief Commercial Officer, Onco360.

Key Points: 
  • “Onco360 is honored to partner with Stemline Therapeutics and become a specialty pharmacy provider for ORSERDU patients,” said Benito Fernandez, Chief Commercial Officer, Onco360.
  • 68% of newly diagnosed breast cancer patients will have the hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative subtype.
  • Additionally, dependent on tumor size and extent of lymph node involvement, 13-41% of early-stage breast will recur with distant metastatic disease.
  • Unfortunately, the five-year overall survival (OS) for metastatic breast cancer patients is only 30%.1,2,3
    ORSERDU is commercialized by Stemline Therapeutics, Inc., a Menarini Group Company.

Bobcat Company Compact Loader Creators Inducted into National Inventors Hall of Fame

Retrieved on: 
Monday, January 9, 2023
Automotive Manufacturing, Residential Building & Real Estate, Manufacturing, Commercial Building & Real Estate, Construction & Property, Machinery, Landscape, Attention, Keller (automobile), Entrepreneurship, Aromatase, ReCAPTCHA, Minnesota State Fair, Gwinner–Roger Melroe Field, Growth, Creativity, Farmer, Bobcat Company, Hormone, NIHF, M400, Invention, Table, Keller, Food, Heavy equipment, Bobcat

In 1957, the Kellers built a three-wheeled loader with two drive wheels in front and a caster wheel in the rear – the precursor to the modern skid-steer loader.

Key Points: 
  • In 1957, the Kellers built a three-wheeled loader with two drive wheels in front and a caster wheel in the rear – the precursor to the modern skid-steer loader.
  • The loader came to the attention of Melroe Manufacturing Company (now Bobcat Company ), which invited the Kellers to demonstrate their invention in their booth at the Minnesota State Fair in 1958.
  • To improve on the design of the loader, a second set of drive wheels was added to the back of the loader in 1960.
  • It is a recognition for all of the early and current Bobcat employees who have helped bring our little ‘Keller loader’ to be the Bobcat machine it is today.

Guardant Health Announces Collaboration With AstraZeneca to Develop Companion Diagnostic to Identify Patients With ESR1-mutated Metastatic Breast Cancer

Retrieved on: 
Thursday, December 8, 2022
Oncology, Health, Genetics, Research, Pharmaceutical, Science, Security (finance), III, Analysis, ESR1, Financial condition report, Patient, Annual report, Breast cancer, AstraZeneca, GH, Aromatase, Health, Liquid biopsy, Result, Helmy Eltoukhy, Pharmaceutical industry

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today it has entered into a collaboration with AstraZeneca to pursue the development, regulatory approval and commercialization of the Guardant360 CDx blood test as a companion diagnostic to identify patients with ESR1-mutated metastatic breast cancer.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today it has entered into a collaboration with AstraZeneca to pursue the development, regulatory approval and commercialization of the Guardant360 CDx blood test as a companion diagnostic to identify patients with ESR1-mutated metastatic breast cancer.
  • Were pleased to collaborate with AstraZeneca on this important study for breast cancer patients, said Helmy Eltoukhy, Guardant Health chairman and co-CEO.
  • Guardant Health has commercially launched Guardant360, Guardant360 CDx, Guardant360 TissueNext, Guardant360 Response, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal for early-stage cancer patients.
  • The Guardant Health screening portfolio, including the ShieldTM test, aims to address the needs of individuals eligible for cancer screening.

Camizestrant Significantly Delayed Disease Progression in Advanced ER-Positive Breast Cancer, Adding at Least 3.5 Months Benefit Versus FASLODEX® (fulvestrant)

Retrieved on: 
Thursday, December 8, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, QT, Hypersensitivity, ESR1, Hypocalcemia, Peripheral neuropathy, Anemia, Angioedema, Headache, AstraZeneca, Syncope, Woman, Duane syndrome, Hives, Xeroderma, Paced Auditory Serial Addition Test, Leukopenia, Sciatic nerve, Risk, Indigestion, Thrombocytopenia, Lung, Rash, Myalgia, Liver, Fatigue, Pain, Back pain, US Foods, Photopsia, Birth, Immunoassay, Constipation, Hair, Infant, Infection, Food, Neutropenia, Bleeding, Bradycardia, Pregnancy, Dysgeusia, Cough, Diarrhea, Estradiol, Itch, PFS, Tears, Neuralgia, CI, Purging disorder, Grade, Mutation, Xerostomia, Vertigo, Patient, Fulvestrant, Nausea, Vomiting, Incidence, Aromatase, Breathe Me, Arthralgia, Erythema, Bone pain, Stomatitis, Weakness, Sciatica, Fetus, Neuropathic pain, Appetite, Pharmaceutical industry, Vaccine, Dietary supplement, Fever

AstraZeneca has a broad clinical development program for camizestrant in advanced breast cancer.

Key Points: 
  • AstraZeneca has a broad clinical development program for camizestrant in advanced breast cancer.
  • Advise women of reproductive potential to use effective contraception during FASLODEX treatment and for 1 year after the last dose.
  • SERENA-2 is a randomized, open-label, parallel group, multicenter Phase II trial evaluating camizestrant at several dose levels compared to FASLODEX in advanced ER-positive, HER2-negative breast cancer.
  • The primary endpoints are PFS defined by response evaluation criteria in solid tumors (RECIST) version 1.1 for 75mg camizestrant versus FASLODEX and for 150mg camizestrant versus FASLODEX.

Systems Oncology to Present Positive Preclinical Data for SERA2 at J.P. Morgan 41st Annual Healthcare Conference

Retrieved on: 
Tuesday, December 6, 2022
Oncology, Health, Health Technology, Research, Science, Pharmaceutical, Biotechnology, ER, Chemistry, Baylor University Medical Center, UPR, Champaign County, Illinois, Oncology, J. P. Morgan, Intellectual property, IP, Patient, SERA, Research, Biology, Breast cancer, SO, Aromatase, Unfolded protein response, Selective estrogen receptor degrader, McKesson Corporation, Cell death, University, Selective estrogen receptor modulator, Medical imaging, Pharmaceutical industry

Systems Oncology today announced they will be presenting positive preclinical data on the companys next generation estrogen receptor positive drug candidate, SERA2 (Selective Estrogen Receptor Activator).

Key Points: 
  • Systems Oncology today announced they will be presenting positive preclinical data on the companys next generation estrogen receptor positive drug candidate, SERA2 (Selective Estrogen Receptor Activator).
  • In the preclinical data presented at J.P. Morgan, treatment with SERA2 in animal models of human breast cancer results in multiple, complete, durable tumor regressions.
  • These data support the rationale for SERA2 as a novel therapeutic for the treatment of breast cancer and potentially other estrogen receptor positive cancers.
  • Systems Oncology will be having partnering meetings during the J.P. Morgan conference from January 9 to January 11, 2023.

Goodness Growth Holdings Celebrates the Life and Legacy of Dr. Jay Westwater with Special Event

Retrieved on: 
Tuesday, December 6, 2022
Aromatase, Plant, MD, Life, Growth, IP, CSE, Medical cannabis, AIMSS, Patient, Cancer, Cancer pain, Breast cancer classification, Science, Research, Breast cancer, Woman, Quality of life, Emergency department, Cannabis, Medical device, United Hospital, Produce

MINNEAPOLIS, Minn., Dec. 6, 2022 /PRNewswire/ -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a physician-led, science-focused cannabis company and IP developer, today announced that it celebrated the life and legacy of Dr. Jay Westwater and the continued advancement of research into cannabis and cancer with a special event on Thursday, Dec. 1.

Key Points: 
  • At the Dec. 1 event, members of Dr. Westwater's family joined representatives from Goodness Growth and other community participants to celebrate his life and the impact he had on his patients and the greater Minneapolis community.
  • Representatives from the Minnesota Office of Medical Cannabis and Dr. Westwater's former coworkers from United Hospital in St. Paul also attended.
  • Goodness Growth also launched its new "Dr. Westwater" brand, a line of topical cannabis products named in honor of Dr. Westwater, at the event.
  • Goodness Growth Holdings, Inc., is a physician-led, science-focused holding company whose mission is to bring the power of plants to the world.

Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study

Retrieved on: 
Monday, November 14, 2022
Cream, Trial of the century, Tablet, Breast cancer, Intravaginal administration, Safety, Disease, Fertility, Risk, Plasma, Prevalence, Organon, Birth, PK, Form, Aromatase, Social media, Vaginal discharge, Survivor, Personal lubricant, Progesterone, Inflammation, Intellectual property, Pain, Tamoxifen, COVID-19, Health, Vulvar cancer, FDA, Failure, SERM, Quality of life, Female, Pharmacokinetics, Bacterial vaginosis, Recurrence, Food, Woman, Oncology, 8-K, Health minister, Dyspareunia, PD, Menopause, Tissue, History, Patient, Birth control, Pharmaceutical industry, VVA, Bayer

SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced topline data from its Phase 1/2 clinical study of DARE-VVA1, a novel intravaginal proprietary formulation of tamoxifen being developed for the treatment of moderate to severe vulvar and vaginal atrophy. The randomized, double-blind, placebo-controlled study was designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of DARE-VVA1 in postmenopausal participants with moderate to severe VVA. The topline data from the study demonstrated safety and tolerability of DARE-VVA1, as well as improvement in the vaginal cytology parameters and the bothersome vaginal symptoms associated with VVA. DARE-VVA1 has the potential to be the first therapeutic specifically approved for the treatment of VVA in U.S. patients with HR+ breast cancer. There are currently no FDA-approved products labeled for VVA treatment in HR+ breast cancer patients.

Key Points: 
  • We are highly encouraged by the positive topline results of the Phase 1/2 study of DARE-VVA1 as this study is a critical step in developing a potential non-hormonal treatment alternative for VVA, said Dr. Annie Thurman, Medical Director of Dar Bioscience.
  • The Phase 1/2 study evaluated different doses of DARE-VVA1, a tamoxifen vaginal insert, in 17 postmenopausal women with VVA.
  • The study was a randomized, multi-center, double-blind, parallel-arm, placebo-controlled, dose-ranging study that evaluated the safety, tolerability, plasma pharmacokinetics (PK) and pharmacodynamics (PD) of DARE-VVA1.
  • Dar plans to submit data from the Phase 1/2 clinical study of DARE-VVA1 for publication in a peer-reviewed publication.

Pharmactive Unveils its Novel Damiana Extract For Him and Her

Retrieved on: 
Tuesday, October 25, 2022
Nutraceutical, Female, Culture, Flavonoid, Testosterone, Woman, GMP, CGMP, Family, HPLC, Halal, Relaxation, Research, High-performance liquid chromatography, Man, NO, Glucoside, Libido, Friends, Aromatase, Health minister, CEO, University, Literature, Central nervous system, Male, Birth control, Dietary supplement, Aztecs

MADRID, Oct. 25, 2022 /PRNewswire/ -- Nutraceutical experts Pharmactive Biotech Products, S.L.U., launches Liboost®, a novel botanical extract of Damiana (Turnera diffusa), as the first formulation to help enhance sexual function in both men and women. Its -sexual performance boosting capabilities have been confirmed in a consumer study conducted by the company yielding impressive results. An in vitro study also supports damiana's ability to modulate the activity of aromatase, an enzyme important in human sexual function.

Key Points: 
  • More recently it has been endorsed as a tonic to help the central nervous system, and for supporting general hormone balance.
  • Pharmactive sources its damiana raw material from Mexico, where it traditionally grows and is manufactured in its highly controlled GMP certified plant in Madrid.
  • With high standards and dedicated R&D investment, Pharmactive was the first company to introduce saffron extract for mood improvement.
  • Pharmactive partners internationally with universities and research organizations to boost its R&D capabilities and generate new opportunities for its customers.

Sermonix Pharmaceuticals Shares Additional Findings From Its ELAINE 1 Clinical Study at the 4th Annual Congress of the International Society of Liquid Biopsy

Retrieved on: 
Friday, October 21, 2022
ESR1, Therapy, PFS, Woman, NASDAQ, Patient, Drug development, Biology, Neoplasm, Aromatase, International Society, Mutation, MAF, CBR, MBC, Liquid biopsy, Menopause, Metastatic breast cancer, Â, Breast cancer, Safety, GLOBE, Fulvestrant, Lasofoxifene, ER, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Poster, Ligand Pharmaceuticals, Duke University, Medical imaging, Pharmaceutical industry, SERM

Investigators evaluated mutant allele fraction (MAF) ctDNA dynamics following treatment with lasofoxifene or fulvestrant.

Key Points: 
  • Investigators evaluated mutant allele fraction (MAF) ctDNA dynamics following treatment with lasofoxifene or fulvestrant.
  • PFS and CBR were 6.04 months and 37% for lasofoxifene versus 4.04 months and 22% for fulvestrant, respectively.
  • Paul Plourde, M.D., vice president of oncology clinical development, has many decades of experience in the oncology drug development arena.
  • Sermonix non-executive chairman of the board is Anthony Wild, Ph.D., former president of both Parke-Davis Pharmaceuticals and Warner-Lamberts Pharmaceutical Division.